---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009166"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:42:45.569314+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences reports 2022 net loss of $55.3M; cash $251.2M; TYRA-300 in clinic for oncology and achondroplasia

## Summary
- Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.
- Cash and equivalents $251.2M as of Dec 31, 2022; provides >2 years runway.
- Initiated patient dosing with TYRA-300 in Phase 1/2 SURF301 oncology study in Nov 2022.
- Expanded TYRA-300 development into achondroplasia; IND planned for Phase 2 in 2024.
- FDA cleared IND for TYRA-200 Phase 1 study in FGFR-resistant cholangiocarcinoma; first patient expected 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-009166
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/0000950170-23-009166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/tyra-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009166
- JSON: https://secwatch.observer/filing/0000950170-23-009166.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009166.txt

## Key facts
- Earnings Releases
  Tyra Biosciences, Inc. reported financial results for the quarter and fiscal year ended December 31, 2022.
  - Period: the quarter and fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 22, 2023, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1863127/000095017023009166/0000950170-23-009166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.